new to hou

Houston software company to launch innovation lab for enterprise startups

The lab will launch virtually first, before moving into a physical space early next year. Photo via Getty Images

A Houston-based global software development company has teamed up to create an innovation lab that will launch virtually before moving into a physical space early next year.

Softeq Development Corporation announced the creation of the Softeq Innovation Lab in partnership with the Massachusetts Institute of Technology's Integrated Design and Management program and Massachusetts-based Boundless Technology. The lab is directed at helping enterprise companies collaborate on the technologies of tomorrow, according to a news release.

"At the Softeq Innovation Lab, we recognize the importance of developing an incubator that goes beyond innovation theatre and are rolling up our sleeves to achieve transformative disruption in enterprise companies," says Christopher A. Howard, Softeq founder and CEO, in the release.

"The first wave of disruption was based in Silicon Valley," he continues. "The second wave of disruption is occurring in industries central to Houston's economy such as energy, health care, and financial services. With technology rewriting the playbooks for these industries, Houston is the perfect venue for our Innovation Lab to enable companies to thrive in this new age of disruption."

First up for the lab is a series of Boundless Bootcamps, which aims to connect participants to corporate disruptors, including David Rose of Warby Parker and MIT Media Lab.

"The city of Houston is at the center of a powerful convergence between industry, innovation and proven intrapreneurs," says Chuck Goldman, principal at Boundless Technology, in the release. "The Softeq Innovation Lab brings together entrepreneurs, corporations and 20X innovators who have achieved ROI of at least 20X and built billion-dollar businesses."

In addition to having access to MIT, Boundless, and Softeq's global networks, the participants will also receive an MIT IDM Certification from the nation's top engineering, design, and business program.

"I'm thrilled to bring our leadership and human-centered design program to Houston to help intrapreneurs drive breakthrough growth in leading organizations" says Matt Kressy, founding director MIT IDM, in the release.

For additional information or to find out more about how to get involved please visit the Softeq Innovation Lab's website.

Trending News

 
 

Promoted

A research team housed out of the newly launched Rice Biotech Launch Pad received funding to scale tech that could slash cancer deaths in half. Photo via Rice University

A research funding agency has deployed capital into a team at Rice University that's working to develop a technology that could cut cancer-related deaths in half.

Rice researchers received $45 million from the National Institutes of Health's Advanced Research Projects Agency for Health, or ARPA-H, to scale up development of a sense-and-respond implant technology. Rice bioengineer Omid Veiseh leads the team developing the technology as principal investigator.

“Instead of tethering patients to hospital beds, IV bags and external monitors, we’ll use a minimally invasive procedure to implant a small device that continuously monitors their cancer and adjusts their immunotherapy dose in real time,” he says in a news release. “This kind of ‘closed-loop therapy’ has been used for managing diabetes, where you have a glucose monitor that continuously talks to an insulin pump. But for cancer immunotherapy, it’s revolutionary.”

Joining Veiseh on the 19-person research project named THOR, which stands for “targeted hybrid oncotherapeutic regulation,” is Amir Jazaeri, co-PI and professor of gynecologic oncology at the University of Texas MD Anderson Cancer Center. The device they are developing is called HAMMR, or hybrid advanced molecular manufacturing regulator.

“Cancer cells are continually evolving and adapting to therapy. However, currently available diagnostic tools, including radiologic tests, blood assays and biopsies, provide very infrequent and limited snapshots of this dynamic process," Jazaeri adds. "As a result, today’s therapies treat cancer as if it were a static disease. We believe THOR could transform the status quo by providing real-time data from the tumor environment that can in turn guide more effective and tumor-informed novel therapies.”

With a national team of engineers, physicians, and experts across synthetic biology, materials science, immunology, oncology, and more, the team will receive its funding through the Rice Biotech Launch Pad, a newly launched initiative led by Veiseh that exists to help life-saving medical innovation scale quickly.

"Rice is proud to be the recipient of the second major funding award from the ARPA-H, a new funding agency established last year to support research that catalyzes health breakthroughs," Rice President Reginald DesRoches says. "The research Rice bioengineer Omid Veiseh is doing in leading this team is truly groundbreaking and could potentially save hundreds of thousands of lives each year. This is the type of research that makes a significant impact on the world.”

The initial focus of the technology will be on ovarian cancer, and this funding agreement includes a first-phase clinical trial of HAMMR for the treatment of recurrent ovarian cancer that's expected to take place in the fourth year of THOR’s multi-year project.

“The technology is broadly applicable for peritoneal cancers that affect the pancreas, liver, lungs and other organs,” Veiseh says. “The first clinical trial will focus on refractory recurrent ovarian cancer, and the benefit of that is that we have an ongoing trial for ovarian cancer with our encapsulated cytokine ‘drug factory’ technology. We'll be able to build on that experience. We have already demonstrated a unique model to go from concept to clinical trial within five years, and HAMMR is the next iteration of that approach.”

Trending News

 
 

Promoted